Phase 3 N=78 ESP Block VS TAP in Laparoscopic Hysterectomy
Hysterectomy
Primary: Visual Analogue Scale (VAS) Pain Scores at Rest at 1 Hour. — 2.8; 3 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients
Acute Myelogenous Leukemia
Primary: Median Overall Survival — 6.9 months
N/A N=26 Magnetic Stimulation to Treat VT Storm
Ventricular Tachycardia
Primary: Ventricular Tachycardia - Incidence of Ventricular Tachycardia on Inpatient Telemetry Monitoring — 7; 4 Participants
Phase 2 N=20 The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma
Glioma
Primary: Proportion of Participants With Progression-free Survival — 0.85 Proportion of participants
Phase 2 N=30 Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Plasma Cell Myeloma · Transplant-Related Carcinoma
Primary: Number of Participants With Adverse Events, Graded According to CTCAE Version 4.0 — 30 Participants
N/A N=30 LINX Reflux Management System in Subjects With GERD Who Have Previously Undergone a Laparoscopic Sleeve Gastrectomy
GERD · Gastroesophageal Reflux Disease
Primary: Percentage of Participants Reporting Greater Than or Equal to (>=) 50 Percent (%) Reduction in Total Gastroesophageal Reflux Disease (GERD)- Health-Related Quality of…
Phase 2 N=65 Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer
Gastroesophageal Cancer
Primary: Progression-Free Survival (PFS) — 3.8 months
Phase 2 N=10 Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
MGMT-unmethylated Glioblastoma (GBM) · GBM
Primary: 1-year Overall Survival (OS) — 80 percentage of participants
Phase 2 N=10 Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia
Anemia · Kidney Disease
Primary: Mean Change From Baseline in Hemoglobin (Hgb) on Day 29 — 9.91; 0.63 Grams per decilitre (g/dL) — p=0.0020
Phase 2 N=94 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis
Anemia · End Stage Renal Disease
Primary: Change From Pre-dose Average in Hemoglobin (Hgb) Level to The Mid-study Average — 10.43; 10.55; 10.52; 0.00 Grams per deciliter (g/dL)
N/A N=14 Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease
Alzheimer Disease
Primary: Change in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog) — 0.94; 1.4 Ratio — p=0.07
Phase 3 N=1,645 A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis
Atopic Dermatitis
Primary: Responder and Partial Responders (RPR): Percentage of Participants From Monotherapy Studies (JAHL, JAHM) Who Achieved a Response of Investigator's Global Assessment…
N/A N=1,820 Reducing Inequities in Care of Hypertension, Lifestyle Improvement for Everyone (RICH LIFE Project)
Uncontrolled Hypertension
Primary: Number of Participants With Controlled Blood Pressure — 462; 442 Participants — p=0.68
Phase 2 N=62 Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Neuroendocrine Cancer
Primary: Overall Response Rate (ORR) — 3.226 percentage of participants
Phase 3 N=154 A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
Type 2 Diabetes
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26 — 0.5; -0.7 percentage of HbA1C — p=<0.001